Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment (vol 12, pg 134, 2010)

被引：7
|
作者：
Hecker, M.
Goertsches, R. H.
Fatum, C.
Koczan, D.
Thiesen, H-J
Guthke, R.
Zettl, U. K.
机构：
来源：
PHARMACOGENOMICS JOURNAL | 2012年 / 12卷 / 04期
关键词：
D O I：
10.1038/tpj.2011.12
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Correction to: The Pharmacogenomics Journal (2012) 12, 134–146; doi:10.1038/tpj.2010.77 Elements were omitted from the Supplementary Information that accompanied the online version of this article. For Supplementary Table 1, the following information should have been included: ‘A list of 121 genes up- or downregulated during first 4 weeks of intramuscular IFN-β-1a treatment.
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [1] Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment
    M Hecker
    R H Goertsches
    C Fatum
    D Koczan
    H-J Thiesen
    R Guthke
    U K Zettl
    The Pharmacogenomics Journal, 2012, 12 : 134 - 146
  • [2] Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment
    Hecker, M.
    Goertsches, R. H.
    Fatum, C.
    Koczan, D.
    Thiesen, H-J
    Guthke, R.
    Zettl, U. K.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (02): : 134 - 146
  • [3] Erratum: Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment
    M Hecker
    R H Goertsches
    C Fatum
    D Koczan
    H-J Thiesen
    R Guthke
    U K Zettl
    The Pharmacogenomics Journal, 2012, 12 : 360 - 360
  • [4] Network Analysis of Transcriptional Regulation in Response to Interferon-β-1a Multiple Sclerosis Treatment Suggests a Molecular Basis for Adverse Effects
    Hecker, Michael
    Goertsches, Robert H.
    Fatum, Christian
    Koczan, Dirk
    Thiesen, Hans-Juergen
    Guthke, Reinhard
    Zettl, Uwe K.
    NEUROLOGY, 2010, 74 (09) : A416 - A416
  • [5] Interferon-β1a for the treatment of multiple sclerosis
    Clerico, Marinella
    Contessa, Giulia
    Durelli, Luca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 535 - 542
  • [6] Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis
    Miller, DH
    Leary, SM
    Thompson, AJ
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S56 - S57
  • [7] Lobular panniculitis and lipoatrophy of the thighs with interferon-β1a for intramuscular injection in a patient with multiple sclerosis
    Weise, Gesa
    Hupp, Markus
    Kerstan, Andreas
    Buttmann, Mathias
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (09) : 1312 - 1313
  • [8] Intramuscular interferon-β-1a -: In patients at high risk of developing clinically definite multiple sclerosis
    Asif, M
    Siddiqui, A
    Wellington, K
    CNS DRUGS, 2005, 19 (01) : 55 - 61
  • [9] Intramuscular interferon-β-1a: In patients at high risk of developing clinically definite multiple sclerosis
    Siddiqui M.A.A.
    Wellington K.
    CNS Drugs, 2005, 19 (1) : 55 - 61
  • [10] Quality of life in multiple sclerosis:: influence of interferon-β1a (Avonex®) treatment
    Vermersch, P
    de Seze, J
    Delisse, B
    Lamaire, S
    Stojkovic, T
    MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (05) : 377 - 381
12345